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Reproductive tract infections have long been hypothesized to increase the risk of uterine fibroids. Few studies have
been conducted, even for the common infection genitalChlamydia trachomatis (gCT), and only with self-reported gCT
data. Our investigation used micro-immunofluorescence serology for gCT to characterize past exposure. We used
cross-sectional enrollment data from a prospective fibroid study carried out in the Detroit, Michigan, area; ultrasound
examinations systematically screened for fibroids. Participants were African-American women aged 23–34 years (re-
cruited in 2010–2012). Age- and multivariable-adjusted logistic regression models were used to estimate odds ratios.
A total of 1,587 women (94% of participants) had unequivocal gCT serology results; 22% had fibroids. Those who
were seropositive for gCT were less likely to have fibroids (age-adjusted odds ratio = 0.68, 95% confidence interval:
0.54, 0.87; multivariable-adjusted odds ratio = 0.80, 95% confidence interval: 0.62, 1.03). Inverse associations were
similar across categories of fibroid size, number, and total volume. Participant groups likely to have had multiple or
severe infections (multiple serovar groups, more sex partners, clinically diagnosed chlamydia) all showed statistically
significantly reduced odds of fibroids. A protective association of gCT with fibroids was unexpected but plausible. gCT
infection might increase immune surveillance and eliminate early lesions. Further investigation on the relationship
between fibroid development and reproductive tract infections is needed.
Chlamydia trachomatis; serology; uterine fibroids
Abbreviations: aOR, multivariable-adjusted odds ratio; CI, confidence interval; gCT, genital Chlamydia trachomatis; RTI,
reproductive tract infection; SELF, Study of Environment, Lifestyle and Fibroids.
Uterine fibroids, hormonally dependent benign tumors of
the uterine smooth muscle, are one of the most common gyne-
cological conditions affecting reproductive-age women in the
United States (1). However, their etiological causes are largely
unknown. Infectious agents have been linked to several neo-
plasms, with approximately 18% of cancers estimated to be due
to infection (2). Infection may also increase the risk of fibroid
development. Such an association has been hypothesized since
the 1930s regarding reproductive tract infections (RTIs). Both
RTIs and fibroids disproportionately burden African-American
women, and certainRTIs, such as genitalChlamydia trachomatis
(gCT), are very common (approximately 3 million new gCT
infections annually (3)) and can cause chronic pelvic infection.
The hypothesis that gCT could play a role in fibroid devel-
opment is consistent with a theorized mechanism of infection-
induced fibroid pathogenesis. gCT infection could stimulate an
inflammatory immune response, which could facilitate the ini-
tiation of tissue damage resulting in tissue repair/regeneration
(increased extracellular matrix, cell proliferation, decreased apo-
ptosis), leading to the formation and growth of uterine fibroids (4,
5). gCT has been isolated from the upper genital tract, including
the cervix (6) and endometrium (7, 8), and has also been found
to infect the placenta (9). Furthermore, gCT has been shown to
cause pelvic inflammatory disease and can lead to subepithelial
inflammation, as well as epithelial ulceration and scarring (10).
However, the limited data on associations of RTIs, particu-
larly gCT, with fibroid risk (11–13) have yielded inconsistent
findings. One case-control study found suggestions of positive
associations of fibroids with self-reported pelvic inflammatory
disease (11) and gCT (11); a cross-sectional study found a
procedure for the detection and diagnosis of fibroids (23), at one
of 3 Henry Ford Health System clinics. Focal fibroids 0.5 cm
or more in diameter were measured in triplicate. For each mea-
surement, the 3 perpendicular diameters (longitudinal, anterior-
posterior, and transverse) were recorded.
Outcome definitions
The primary outcome of this studywas the presence offibroids
(yes/no) at the enrollment transvaginal ultrasound. Participants
with at least 1 fibroid greater than or equal to 0.5 cm in diameter
at enrollment were considered to have fibroids, and all women
without a fibroid greater than or equal to 0.5 cm in diameter were
considered not to have fibroids. The secondary outcomes for this
analysis were size of the largest fibroid (cm), number of fibroids,
and total fibroid volume (cm3) (seeWebAppendix 1, available at
https://academic.oup.com/aje, for definitions).
Chlamydia assessment
The presence of serum immunoglobulin G antibodies to gCT
was determined bymeans of amicro-immunofluorescence assay
(24), which is the gold standard serological method. This assay
can detect species-specific chlamydia antibodies and is the only
test that also differentiates between the serovars of gCT.
An experienced laboratory technician at the University of
Washington Chlamydia Laboratory (Seattle, Washington) per-
formed the micro-immunofluorescence test. The laboratory’s
antigen panel includes purified elementary bodies ofC. tracho-
matis (serovars A, B, I, and H and groupings of serovars CJ,
DE, KL3, FG, and L1L2), Chlamydia pneumoniae (serovar
TW183), andChlamydia psittaci (avian strain 6BC). Partici-
pants who tested positive (≥1:16 dilution) for any of the gCT
serovars B, I, H, CJ, DE, KL3, and FGwere considered seropos-
itive for gCT infection. A negative antigen control was included
with each set of antigens on the micro-immunofluorescence
slides, and a positive serum control analysis was run with each
set of sera on a given day.
C. psittaciwas included in the antigen panel to monitor spe-
cies cross-reactive antibody responses. We excluded partici-
pants with species cross-reactivity (where the maximum titer
for serovars B–KL3 was ≥1:16 and identical to the C. psittaci
titer) because theywould not have had a conclusive gCT status.
C. pneumoniae, a common respiratory infection, was used as
a comparison for the gCT findings (see Web Appendix 1 for
more details on the chlamydia assessment protocol).
C. trachomatis serological analysis was conducted for the
98% of participants with available enrollment blood samples
(n = 1,661). Five batches of samples were sent to the labora-
tory. Each batch included blinded duplicate samples for quality
control, and 3 batches included additional positive controls
(Web Appendix 1). All of the blinded samples had the same
gCT serostatus as their duplicate, and each positive control
was positive for gCT based on our definition. After the 74 sam-
ples with the same serological titers for gCT and C. psittaci
were excluded from gCT analyses, our primary analyses were
performed on 1,587 participants. One hundred and sixty sam-
ples had the same titers for C. pneumoniae and C. psittaci and
thus were excluded fromC. pneumoniae analyses.
suggestive positive association for gCT among white women 
(12). In a recent cross-sectional study, we found no positive as-
sociations between self-reported gCT or pelvic inflammatory 
disease and fibroids; in fact, women reporting a history of gCT 
tended to have fewer and smaller fibroids (13). These previous 
studies measured gCT history with self-reported questionnaire 
data, which can be plagued by recall error and misclassification 
due to the asymptomatic nature of gCT (14–17). A serological 
measure of exposure, identifying antibodies in the serum that 
remain after infection, would provide more accurate exposure 
assessment than self-reported gCT.
C. trachomatis antibodies persist years after infection (18); 
serological assays are sensitive and specific markers of past C. 
trachomatis infection (19). There are 19 serovars of C. tracho-
matis, divided into 3 serogroups based on genetic relatedness 
and serological cross-reactivity: serogroup B (serovars B, Ba, D, 
Da, E, L1, L2, and L2a), serogroup C (serovars A, C, H, I, Ia, J, 
K, and L3), and serogroup I (serovars F, G, and Ga). The major-
ity of C. trachomatis genital infections in the United States are 
caused by serovars D–K, primarily D, E, and F (20). Serovars 
A–C are predominately associated with hyperendemic blinding 
trachoma, an eye infection typically found in the Middle East, 
Asia, and Africa; serovar B has also been found to cause genital 
infections (20). Serovars L1–L3 are exclusively associated with 
lymphogranuloma venereum, a systemic sexually transmitted 
infection that is endemic in parts of Africa, Asia, South America, 
and the Caribbean (21).
The aim of our study was to investigate the relationship 
between gCT and fibroids in a large cohort with ultrasound 
screening for fibroids and serological measurement of expo-
sure. To our knowledge, this study was the first to investigate 
the association of fibroids with gCT exposure assessed serolog-
ically. We also explored the relationship between gCT sero-
positivity and number, size, and total volume of fibroids.
METHODS
Study participants and data collection
We used transvaginal ultrasound results, self-reported ques-
tionnaire data, and stored frozen serum specimens from parti-
cipants in the Study of Environment, Lifestyle and Fibroids 
(SELF), an ongoing National Institute of Environmental Health 
Sciences investigation based in the Detroit, Michigan, area. SELF 
is a prospective cohort study of fibroid development; however, 
only baseline fibroid data were available at the time of this analy-
sis. Enrollment data and specimen collection protocols have been 
described previously (22). In brief, from November 2010 to 
December 2012, the investigators recruited 1,696 African-
American female volunteers aged 23–34 years. Women were 
ineligible for SELF if they had a previous diagnosis of uterine 
fibroids or a history of hysterectomy. Participants gave written 
informed consent. The study was approved by the institutional 
review boards of the National Institute of Environmental Health 
Sciences and the Henry Ford Health System (Detroit, Michigan).
Fibroid assessment
As described previously (22), fibroids were assessed by study 
sonographers with transvaginal ultrasonography, the standard
Statistical analyses
Standard descriptive statistics were calculated for all vari-
ables of interest. Missing data were minimal (<1%); complete-
case analysis was performed. Ninety-five percent confidence
intervals were estimated for all odds ratios. All analyses were
conducted with SAS 9.3 (SAS Institute, Inc., Cary, North
Carolina).
Primary analyses. Given the limited prior data, our primary
aim was to identify associations rather than provide quantitative
risk estimates. Thus, logistic regression was used to estimate the
odds ratio for the relationship between gCT serostatus and
fibroid presence. Although relative odds overestimate the rela-
tive risk for associations with an outcome as common as fi-
broids, the statistical test for association is valid. Covariates
were determined on the basis of a review of the literature, and
a directed acyclic graph (25) was used to provide a conceptual
framework. A priori confounders included age (in years), age at
menarche, parity, and use of depot medroxyprogesterone ace-
tate. Alcohol consumption and education were tested as poten-
tial confounders. The alcohol variable reflected the drinking
level eachwoman reported for the age(s) at which shewas drink-
ing themost (see details on covariates inWebAppendix 1). Body
mass index and smoking have not been found to be consistently
associated with fibroids in the literature (12) and were not con-
sidered important risk factors in this analysis.
After use of the 10% change-in-estimate approach, only the
covariates included a priori remained in the final model. Logistic
regression was used to estimate age- and multivariable-adjusted
odds ratios for the relationship between C. pneumoniae serosta-
tus and fibroid presence, for comparison with theC. trachomatis
findings.
Sensitivity analyses. To evaluate the robustness of our
findings, we examined multivariable-adjusted odds ratios for
the association of gCT with fibroids in a series of sensitivity
analyses. First, we repeated the primary analyses while using
both stricter and more liberal definitions of gCT seropositivity
(Web Table 1). Secondly, we excluded women who reported
having undergone cervical treatment, such as cone biopsy, for
removal of possible early cervical cancer lesions (226 of the
1,587 women were excluded, including 1 with missing data
on cervical treatment) because it was previously found to be
inversely associated with fibroids in SELF (26). Thirdly, to
evaluate age as an effect modifier (due to a possible decline
in antibody levels over time), we evaluated the association
between gCT and fibroid presence within 2 age strata (23–29
years and 30–35 years).
We also conducted analyses to investigate the temporality of
gCT exposure in relation to fibroid development. Smaller fi-
broids may have developed more recently as compared with
larger fibroids; thus, we evaluated the association between
gCT and fibroids among strata of the size of the largest fibroid
(<2 cm and ≥2 cm). In addition, we looked at the association
between gCT and fibroid presence within 3 strata of number of
sexual partners before age 20 years (≤1, 2–5, or≥6 sex partners).
Participants withmore sexual partners before age 20 yearswould
have been more likely to be exposed to gCT prior to fibroid
development.
Secondary analyses. We also examined the association
between gCT and size of the largest fibroid, number of fibroids,
and total fibroid volume. Median values were used as category
cutpoints. To estimate the odds ratios for the association of
gCT with each outcome, we used multinomial logistic regres-
sion. We were also interested in severity of infection. Because
most gCT infections are asymptomatic (27), self-reported infec-
tions are likely to be those that are symptomatic and potentially
more severe. Thus, we evaluated the multivariable-adjusted
odds ratios for the association between gCT and fibroid presence
using a 3-level exposure variable: 0 = seronegative, 1 = not
symptomatic (seropositive with no self-reported diagnosis), and
2 = symptomatic (seropositive with a self-reported diagnosis).
In secondary analyses, we adjusted for the same covariates as
in the primary analysis.
Exploratory analyses. We also conducted exploratory
analyses to further understand the relationship between gCT
and fibroids. We estimated the multivariable-adjusted odds
ratios for the association between fibroid presence and the
highest of the gCT titers (seronegative, 1:16–1:64, or 1:128–
1:1,024) and the number of gCT serogroups (seronegative,
1 group, or multiple (2 or 3) groups).
RESULTS
The median age of women in our cohort was 29 years, and
the median age at menarche was 12 years. The majority (61%)
were parous, and over 40% had ever used depot medroxypro-
gesterone acetate. Fifty-seven percent (n = 907) of the partici-
pants were seropositive for gCT; seropositive women tended to
be less educated and were more likely to have ever smoked, to
be heavier alcohol drinkers, to be parous, to have ever used
depot medroxyprogesterone acetate, to have had more sex part-
ners before age 20 years, and to have been younger at first sex
comparedwith those whowere seronegative for gCT (Table 1).
Twenty-two percent (n = 352) of women had fibroids dis-
covered at ultrasound screening. The size of the largest fibroid
was <2 cm for 59%; 61% had only 1 fibroid. The total fibroid
volumewas<2 cm3 for 49% of participants with fibroids.
In primary analyses, the odds of fibroids were lower among
women who were seropositive for gCT than among those who
were seronegative, although the association was weaker and not
statistically significant in the multivariable model (age-adjusted
odds ratio = 0.68, 95% confidence interval (CI): 0.54, 0.87;
multivariable-adjusted odds ratio (aOR) = 0.80, 95% CI: 0.62,
1.03) (Table 2). Depot medroxyprogesterone acetate and parity,
both of which had inverse associations with fibroid prevalence,
had the strongest impact on the multivariable-adjusted associa-
tion. In contrast to the inverse association between fibroids and
gCT, we found no association between fibroids and C. pneumo-
niae in multivariable-adjusted analyses (Table 2), even whenwe
varied the definition forC. pneumoniae (data not shown).
The association between gCT and fibroids remained consis-
tent across most of the sensitivity analyses that varied the defi-
nition of gCT (Web Table 1) and restricted/stratified the results
(Table 3). When analyses were stratified by self-reported num-
ber of sex partners before age 20 years, we observed a potential
dose-response relationship between gCT and fibroids. Women
reporting the highest number of sex partners (≥6) before age
20 years had a more apparent inverse association between gCT
and fibroids (aOR = 0.52, 95%CI: 0.29, 0.93) (Table 3).
In secondary analyses, the inverse associations were similar
across size, number, and volume of fibroids (Figure 1). The
49% of seropositive women who reported a gCT diagnosis
(our measure of symptomatic gCT) had a stronger inverse
association with fibroids (aOR = 0.72, 95% CI: 0.53, 0.99)
than did seropositive women without a self-reported gCT diag-
nosis (Table 4).
The exploratory analysis revealed that participants with 2
or 3 serogroups had a more apparent inverse association with
fibroids (aOR = 0.69, 95% CI: 0.49, 0.99) than those with 1
serogroup (Table 4). However, those with the highest titers
did not have the strongest inverse association (Web Table 2).
Overall, women with more infections and more severe infec-
tions evidenced the strongest protective associations (Figure 2).
DISCUSSION
Our results suggest a robust association of gCT seropositivity
with decreased odds of uterine fibroids. Participants who were
more likely to have been infected more often (those reporting
more sex partners before the age of 20 years and those with mul-
tiple serogroups) and/or who probably had more severe infec-
tions (infections that came to clinical attention) had the strongest
reduced odds of fibroids.
Our findings are consistent with those of a previous study
of self-reported RTIs in this same population which suggested
that women self-reporting gCT tended to have fewer and
Table 1. Selected Enrollment Characteristics of 1,587a African-
AmericanWomenAged 23–34 Years According to Genital
Chlamydia trachomatisSerostatus, Study of Environment, Lifestyle












23–26 274 30 211 31
27–30 309 34 235 35
31–35b 324 36 234 34
Education
High school diploma or
less
254 28 95 14
Some college or
technical school
470 52 324 48
Bachelor’s degree or
more
182 20 261 38
Missing data 1 0
Bodymass indexc
15–24 154 17 164 24
25–29 199 22 130 19
30–34 169 19 137 20
35–80 385 42 249 37
Smoking status
Never smoker 591 65 573 84
Ever smoker 316 35 107 16
Peak alcohol
consumptiond
Light 224 25 193 28
Moderate 265 29 254 37
Heavy 418 46 233 34
Parity
Nulliparous 296 33 329 48
Parous 611 67 351 52
DMPA use
Never used 455 50 455 67
Ever used 452 50 225 33
Age at menarche,
years
7–10e 173 19 116 17
11–19 734 81 564 83
No. of sex partners before
age 20 years
≤1f 148 16 259 38
2–5 471 52 309 45
≥6 287 32 110 16













Age at first intercourse,
years
≤14 321 35 132 19
15–16 341 38 198 29
≥17f 243 27 349 51
Missing data 2 0 1 0
Abbreviations: DMPA, depot medroxyprogesterone acetate; gCT,
genitalChlamydia trachomatis.
a Of the 1,661 participants, 74 were excluded due to genus cross-
reactivity (maximum C. trachomatis titer was greater than or equal to
1:16 and equal toChlamydia psittaci titer).
b No one over age 34 years was recruited, but some 34-year-olds
had turned 35 by the time they underwent ultrasonography.
c Weight (kg)/height (m)2.
d Alcohol consumption at the age at which the participant was drink-
ing the most. Light drinkers were those who never consumed 10 or
more alcoholic drinks in a year. Heavy drinkers were those who usu-
ally consumed 6 or more drinks on days when they drank or con-
sumed 4 or more drinks per sitting at least 2–3 times per month.
Moderate drinkers were all others.
e Categorized to identify early age at menarche, the category asso-
ciated with fibroids.
f Includes participants who reported never having sex.
smaller fibroids (13). In the 2 other studies that have investigated
the association between self-reported gCT and fibroid presence,
the results suggested positive associations between gCT and fi-
broids (11, 12). A clinic-based case-control study of premeno-
pausal women aged 18–55 years showed a positive though
nonsignificant association between gCT and clinically de-
tected fibroids (11). The clinic-based study included a much
broader age range than our population and did not screen for fi-
broids. The Uterine Fibroid Study (12), a cross-sectional study
that used ultrasound to screen randomly selected members of an
urban health plan aged 35–49 years for fibroids, found a nonsig-
nificant positive association of self-reported gCT with fibroids in
white women (12). The Uterine Fibroid Study included an old-
er age group than the women in our study and did not find an
association in African-American women. A small pilot study
found no evidence of latent gCT infection in immunostained
fibroid tissue specimens from 20 Uterine Fibroid Study partici-
pants who had reported a history of sexually transmitted disease
ormultiple sex partners (12).
Our study had several strengths. To our knowledge, it was the
first study to investigate the relationship between gCT and fi-
broids using an immunological measure of exposure. Antibody
titers persist for years postinfection (28) and therefore can iden-
tify gCT infections that occurred years prior to enrollment. Our
blinded quality control samples demonstrated low measurement
error in gCT serostatus. We also had information on gCT sero-
groups and titers. Previous studies have used only self-reported
diagnosis of gCT as the exposure measurement, which is prob-
lematic due to the high prevalence of asymptomatic infection
(27) and moderate specificity (e.g., 21% of seronegative women
in our study reported having been diagnosedwith gCT). Further-
more, we used a standard and valid measure of fibroid status
based on systematic ultrasound screening rather than fibroids
clinically detected because of symptoms or incidental detec-
tion. The number, diameter, and volume of the fibroids were
Table 2. Relationships of GenitalChlamydia trachomatis andChlamydia pneumoniaeSerostatusWith Uterine





Model 1a Model 2b
OR 95%CI OR 95%CINo. %
GenitalC. trachomatis-seropositivec
No 680 174 26 1.00 Referent 1.00 Referent
Yes 907 178 20 0.68 0.54, 0.87 0.80 0.62, 1.03
C. pneumoniae-seropositived
No 447 107 24 1.00 Referent 1.00 Referent
Yes 1,054 232 22 0.89 0.68, 1.17 0.94 0.72, 1.24
Abbreviations: CI, confidence interval; OR, odds ratio.
a Results were adjusted for age.
b Results were adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity.
c Of the 1,661 participants, 74 were excluded due to genus cross-reactivity (maximum C. trachomatis titer was
greater than or equal to 1:16 and equal toChlamydia psittaci titer).
d Of the 1,661 participants, 160 were excluded due to genus cross-reactivity (C. pneumoniae titer was greater than
or equal to 1:8 and equal toC. psittaci titer).
Table 3. Results of Sensitivity Analyses of the Association
Between Uterine Fibroids and GenitalChlamydia trachomatis
Serostatus Among African-AmericanWomen Aged 23–34 Years,








Full sample 1,587b 0.80 0.62, 1.03
Exclusion of womenwith prior
cervical treatment (n = 226)
1,361 0.79 0.60, 1.03
Stratification
By age group, yearsc
23–29 892 0.74 0.51, 1.07
≥30 695 0.85 0.60, 1.21
By size of the largest
fibroid, cmd
None 1,235 1.00 Referent
<2 209 0.80 0.59, 1.09
≥2 143 0.79 0.55, 1.14
By no. of sex partners
before age 20 yearsd,e
0–1 407 1.12 0.68, 1.82
2–5 780 0.81 0.56, 1.15
≥6 397 0.52 0.29, 0.93
a Adjusted for age, age at menarche, depot medroxyprogesterone
acetate use, and parity.
b Of the 1,661 participants, 74 were excluded due to genus cross-
reactivity (maximum C. trachomatis titer was greater than or equal to
1:16 and equal toChlamydia psittaci titer).
c Test of possible decline in antibody levels over time.
d Test of temporality.
e Three participants had missing data for number of sex partners
before age 20 years.
systematically measured, so we could examine associations with
these characteristics. Our sample size was sufficient to pro-
vide good precision for the main hypotheses. Our study also had
extensive data for assessment of potential confounding, minimal
missing data, and sensitivity analyses for evaluating potential
bias.
Our study also had limitations. First, it was a cross-sectional
analysis. Thus, the temporal relationship between gCT infec-
tion and fibroid development is unknown. However, reverse
causation (fibroids developing first and inducing protection
against gCT) has no plausible mechanism, and the timing is
unlikely. gCT infectionwas likely to have begun early. Approx-
imately 63% of new gCT infections in the United States occur
among 15- to 24-year-olds (3), and in our study, the median
time between first self-reported gCT diagnosis and study
enrollment was 9 years. In contrast, development of fibroids
was likely to occur relatively later. Fibroids are rarely seen
in African Americans before the mid-20s (22, 29), and most
of the fibroids detected in our study were small, suggesting
new development.
Secondly, selection bias from the exclusion of women with
previously diagnosed fibroids could be a potential problem. If
those excludedwere substantiallymore likely to have had a prior
gCT infection than those enrolled, such selection could have cre-
ated an artifactual inverse association. However, when we esti-
mated gCT infection rates that would have been necessary in the
excluded women to have substantially changed our results, we
found that nearly 80% of those excluded would have had to
have been gCT-seropositive (see details inWebAppendix 2 and
Web Tables 3 and 4). Such a high infection rate is very unlikely.
Additionally, because the risk of fibroids increases with age,
there would have been many more older women excluded
because of a prior fibroid diagnosis than younger women. There-
fore, if the inverse association was due to selection bias, we
would expect that inverse association to have been stronger in






















Figure 1. Relationships of size of the largest fibroid, number of fibroids, and total fibroid volume with genital Chlamydia trachomatis serostatus
among 23- to 34-year-old African-American women with uterine fibroids (n = 352), Study of Environment, Lifestyle and Fibroids, Detroit, Michigan,
2010–2012. Multivariable-adjusted odds ratios (aORs) were adjusted for age, age at menarche, depot medroxyprogesterone acetate use, and parity.
Bars, 95% confidence intervals (CIs).
Table 4. Relationships of GenitalChlamydia trachomatis
Symptoms and Number of SerogroupsWith Uterine Fibroids Among
African-AmericanWomen Aged 23–34 Years, Study of Environment,












Seronegative 680 174 26 1.00 Referent
Seropositive
Asymptomatic 459 100 22 0.88 0.65, 1.18
Symptomaticd 446 78 17 0.72 0.53, 0.99
No. of serogroupse
Seronegative 680 174 26 1.00 Referent
Seropositive
1 serogroup 310 62 20 0.76 0.54, 1.07
2 or 3
serogroups
310 54 17 0.69 0.49, 0.99
Abbreviations: gCT, genitalChlamydia trachomatis.
a Adjusted for age, age at menarche, depot medroxyprogesterone
acetate use, and parity.
b Of the 1,661 participants, 74 were excluded due to genus cross-
reactivity (maximum C. trachomatis titer was greater than or equal to 
1:16 and equal to Chlamydia psittaci titer); 2 were excluded because 
of missing self-reported data on gCT.
c Limited to participants with data on gCT serostatus and self-
report.
d Participants with a self-reported diagnosis of gCT (n = 2 where 
self-report was missing).
e Of the 1,661 participants, 74 were excluded due to genus cross-
reactivity (maximum C. trachomatis titer was greater than or equal to 
1:16 and equal to C. psittaci titer); 286 were excluded because no 
serovar pattern was available; and 1 was excluded because the sero-
var pattern was L1L2, which is an indication of systemic C. trachoma-
tis, not gCT.
In addition, a large proportion of women who are seropositive for
gCT are unaware of their past infection (15), making it very
unlikely that women without fibroids who had a history of gCT
exposure would be more likely to enroll in the study than those
without gCT; thus, there was limited potential for this type of
selection bias.
Third, uncontrolled confounding is a potential limitation, but
the study’s extensive data collection allowed us to control for all
well-documented risk factors for fibroids and to investigate other
variables as well. In our previous study, there were no strong as-
sociations for any self-reported RTIs (13) or with herpes mea-
sured serologically (30); thus, we did not include other RTIs in
our models. Finally, our sample comprised volunteers, thus
potentially limiting generalizability. However, in our sample, the
self-reported frequency of a history of gCT infection was 38%
and the seroprevalence of gCT was 57%, both consistent with
other reports (15, 31). In addition, the 22% prevalence of fibroids
in our cohort at ultrasound screening fallswithin the range of prior
US studies that conducted ultrasound screening (12, 29, 32, 33).
The inverse association we found was unexpected and con-
trary to our hypothesis but is plausible. There has long been
substantial evidence that bacterial infections can lead to the
spontaneous regression of some tumors (34). The infecting
organism could directly induce antitumor effects, or the infec-
tion could lead to enhancement of immune surveillance (34).
Altough little is known about gCT infection of the uterus, espe-
cially the myometrium, finding gCT in the upper genital tract is
not uncommon (7, 8); the association between gCT and pelvic
inflammatory disease is very well known (35). Smoothmuscle
cells are a target for C. pneumoniae (36–38); thus, it is plausible
that C. trachomatis could infect uterine smooth muscle cells.
In mouse models of chlamydia infection, endometrial infec-
tion appears to lead to subendometrial macrophage influx
(39). gCT appears to persist for at least a year in most women
and even up to 5 years (40) and thus could generate a chronic
inflammatory immune response that might eliminate initial
mutated cells. Preneoplastic lesions have been found to be
more susceptible to apoptosis than normal cells (41, 42). How-
ever, this mechanism would rely on timing of infection during
a period in fibroid development when lesions are small. Women
with more infections or more severe infections would have a
greater probability of being infected with gCT during such a
developmental window of the tumor. Women with more severe
infections evidenced the strongest protective associations. Infor-
mation on the timing of infection is needed to better evaluate this
potential mechanism.
In conclusion, in a large cohort of African-American women
aged 23–34 years, gCT seropositivity was inversely associated
with the presence of fibroids. To investigate this finding fur-
ther, researchers could use fibroid animal models to determine
the impact of an ascending genital chlamydial infection, espe-
cially in the very early stages of fibroid development. The rat
and guinea pig models have been used for both fibroids (43,
44) and chlamydia infection (45, 46), so there is potential for
these 2 conditions to bemodeled together. In addition, prospective
evaluation of the relationship between RTIs and fibroid develop-
ment inwomen is needed.
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Figure 2. Odds of uterine fibroid development according to number
and severity of genital Chlamydia trachomatis (gCT) infections
among 23- to 34-year-old African-American women, Study of Environ-
ment, Lifestyle and Fibroids, Detroit, Michigan, 2010–2012. Partici-
pants who were more likely to have had multiple gCT infections (more
sex partners, more serogroups) or more severe gCT infections (symp-
tomatic) showed statistically significantly reduced odds of fibroids.
Multivariable-adjusted odds ratios were adjusted for age, age at menar-
che, depot medroxyprogesterone acetate use, and parity. White circle,
gCT-seronegative women (referent); black circles, gCT-seropositive
women. Bars, 95% confidence intervals.
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